PT  - JOURNAL ARTICLE
AU  - Hyvärinen, K
AU  - Haimila, K
AU  - Moslemi, C
AU - Blood Service Biobank
AU  - Olsson, ML
AU  - Ostrowski, SR
AU  - Pedersen, OB
AU  - Erikstrup, C
AU  - Partanen, J
AU  - Ritari, J
TI  - A machine-learning method for biobank-scale genetic prediction of blood group antigens
AID  - 10.1101/2023.09.18.23295700
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.09.18.23295700
4099  - http://medrxiv.org/content/early/2023/09/19/2023.09.18.23295700.short
4100  - http://medrxiv.org/content/early/2023/09/19/2023.09.18.23295700.full
AB  - Blood transfusion is a life-saving medical procedure performed routinely worldwide. A key element for successful transfusion is compatibility of the patient and donor red blood cell (RBC) antigens. Precise antigen matching reduces the risk for immunization and other adverse transfusion outcomes. RBC antigens are encoded by specific genes, which allows developing computational methods for determining antigens from genomic data.We describe here a classification method for determining RBC antigens from genotyping array data. Random forest models for 39 RBC antigens in 14 blood group systems and for human platelet antigen (HPA)-1 were trained and tested using genotype and RBC antigen and HPA-1 typing data available for 1,192 blood donors in the Finnish Blood Service Biobank. The algorithm and models were further evaluated using a validation cohort of 111,667 Danish blood donors.In the Finnish test data set, the median (interquartile range [IQR]) balanced accuracy for 39 models was 99.9 (98.9–100)%. We were able to replicate 34 out of 39 Finnish models in the Danish cohort and the median (IQR) balanced accuracy for classifications was 97.1 (90.1– 99.4)%. When applying models trained with the Danish cohort, the median (IQR) balanced accuracy for the 40 Danish models in the Danish test data set was 99.3 (95.1–99.8)%.The RBC antigen and HPA-1 prediction models demonstrated high overall accuracies suitable for probabilistic determination of blood groups and HPA-1 at biobank-scale. Furthermore, population-specific training cohort increased the accuracies of the models. This stand-alone and freely available method is applicable for research and screening for antigen-negative blood donors.Competing Interest StatementM.L. Olsson is an inventor on patents about Vel blood group genotyping (unrelated to the methods and models presented in this study) and owns 50% each of the shares in BLUsang AB, an incorporated consulting firm, which receives royalties for said patents. The other authors declare no conflicts of interest.Funding StatementThe study was partially supported by funding from the Government of Finland VTR funding, the Academy of Finland, the Finnish Cancer Association, and Business Finland. The study of the Danish cohort was supported by Independent Research Fund Denmark (project number 0214-00127B), Bloddonornes forskningsfond, and A.P Moller Fonden. M.L. Olsson is a Wallenberg Clinical Scholar funded by Knut and Alice Wallenberg Foundation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Finnish study cohort consists of 1,192 blood donors belonging to the Blood Service Biobank, Helsinki, Finland (https://www.veripalvelu.fi/en/biobank/). Genotype and blood group phenotype data were obtained from the Blood Service Biobank. The study (biobank decision 002-2018) conforms to the principles of the Finnish Biobank Act (688/2012) and the participants have given written informed consent to the Blood Service Biobank. The Danish validation cohort consists of 111,667 participants of the Danish Blood Donor Study (DBDS) Genomic Cohort expanding on the Danish blood bank system22,23. The genetic studies in DBDS have been approved by the Danish Data Protection Agency (P-2019-99) and the Scientific Ethical Committee system (NVK-1700407). I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesGenotyping and RBC antigen/phenotype and HPA-1 typing data for the Finnish cohort are stored in the Blood Service Biobank, Helsinki, Finland. Researchers may apply for access to data (https://www.veripalvelu.fi/en/biobank/for-researchers/). Due to privacy laws, the Danish genetic data and phenotypes are only available to DBDS researchers and blood banks. https://www.veripalvelu.fi/en/biobank/for-researchers/